Fluoroquinolone resistance in ophthalmology and the potential role for newer ophthalmic fluoroquinolones

Survey of Ophthalmology

Volumn 49, Issue 2 SUPPL. 2, 2004, Pages

  Hwang, David G ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Antimicrobial resistance; Endophthalmitis; Fluoroquinolones; Gatifloxacin keratitis; Levofloxacin; Moxifloxacin

Indexed keywords

CIPROFLOXACIN; GATIFLOXACIN; LEVOFLOXACIN; MOXIFLOXACIN; NORFLOXACIN; OFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ANTIBIOTIC RESISTANCE; CONJUNCTIVITIS; DRUG PENETRATION; DRUG POTENCY; GRAM POSITIVE COCCI; HUMAN; KERATITIS; MYCOBACTERIUM; OPHTHALMOLOGY; PRIORITY JOURNAL; REVIEW;

EID: 1542708136     PISSN: 00396257     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.survophthal.2004.01.004     Document Type: Article

References (17)

1. Alexandrakis G., Alfonso E.C., Miller D. Shifting trends in bacterial keratitis in South Florida and emerging resistance to fluoroquinolones. Ophthalmology. 107:2000;1497-1502.
2. Blondeau J.M., Zhao X., Hansen G., Drlica K. Mutant prevention concentrations of fluoroquinolones for clinical isolates of Streptococcus pneumoniae. Antimicrob Agents Chemother. 45:2001;433-438.
3. Boswell F.J., Andrews J.M., Jevons G., Wise R. Comparison of in vitro activities of several new fluoroquinolones against respiratory pathogens and their abilities to select fluoroquinolone resistance. J Antimicrob Chemother. 50:2002;495-502.
4. Chaudhry N.A., Flynn H.W., Murray T.G., et al. Emerging ciprofloxacin-resistant Pseudomonas aeruginosa. Am J Ophthalmol. 128:1999;509-510.
5. Dalhoff A., Schmitz F.J. In vitro antibacterial activity and pharmacodynamics of new quinolones. Eur J Clin Microbiol Infect Dis. 22:2003;203-221.
6. Goldstein M.H., Kowalski R.P., Gordon J. Emerging fluoroquinolone resistance in bacterial keratitis: a 5-year review. Ophthalmology. 106:1999;1313-1318.
7. Kowalski R.P., Dhaliwal D.K., Karenchak L.M., et al. Gatifloxacin and moxifloxacin: an in vitro susceptibility comparison to levofloxacin, ciprofloxacin, and ofloxacin using bacterial keratitis isolates. Am J Ophthalmol. 136:2003;500-505.
8. Leeming J.P. Treatment of ocular infections with topical antibacterials. Clin Pharmacokinet. 37:1999;351-360.
9. Liesegang T.J. Use of antimicrobials to prevent postoperative infection in patients with cataracts. Curr Opin Ophthalmol. 12:2001;68-74.
10. Liesegang T.J. Prophylactic antibiotics in cataract operations. Mayo Clin Proc. 72:1997;149-159.
11. Mather R., Karenchak L.M., Romanowski E.G., Kowalski R.P. Fourth generation fluoroquinolones: new weapons in the arsenal of ophthalmic antibiotics. Am J Ophthalmol. 133:2002;463-466.
12. O'Brien T.P., Maquire M.G., Fink N.E., et al. Efficacy of ofloxacin versus cefazolin and tobramycin in the therapy of bacterial keratitis. Report from the Bacterial Keratitis Research Group. Arch Ophthalmol. 113:1995;1257-1265.
13. Saravoltz L., Manzor O., Check C., et al. Antimicrobial activity of moxifloxacin, gatifloxacin and six fluoroquinolones against Streptococcus pneumoniae. J Antimicrob Chemother. 47:2001;875-877.
14. Smith A., Pennefather P.M., Kaye S.B., Hart C.A. Fluoroquinolones. Place in ocular therapy. Drugs. 61:2001;747-761.
15. Watanabe K., Numata-Watanabe K., Hayasaka S. Methicillin-resistant staphylococci and ofloxacin-resistant bacteria from clinically healthy conjunctivas. Ophthalmic Res. 33:2001;136-139.
16. Wilhelmus K.R., Hyndiuk R.A., Caldwell D.R., et al. 0.3% ciprofloxacin ophthalmic ointment in the treatment of bacterial keratitis. Arch Ophthalmol. 111:1993;1210-1218.
17. Zhao X., Drlica K. Restricting the selection of antibiotic-resistant mutants: a general strategy derived from fluoroquinolone studies. Clin Infect Dis. 33:(Suppl 3):2001;S147-S156.